Last reviewed · How we verify
rVSVΔG-ZEBOV-GP, V920
At a glance
| Generic name | rVSVΔG-ZEBOV-GP, V920 |
|---|---|
| Sponsor | Centre de Recherche Médicale de Lambaréné |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola (PHASE2)
- Partnership for Research on Ebola VACcinations (PHASE2)
- Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rVSVΔG-ZEBOV-GP, V920 CI brief — competitive landscape report
- rVSVΔG-ZEBOV-GP, V920 updates RSS · CI watch RSS
- Centre de Recherche Médicale de Lambaréné portfolio CI